CN112190555B - 一种雷美替胺舌下片及其制备方法 - Google Patents
一种雷美替胺舌下片及其制备方法 Download PDFInfo
- Publication number
- CN112190555B CN112190555B CN202010925379.2A CN202010925379A CN112190555B CN 112190555 B CN112190555 B CN 112190555B CN 202010925379 A CN202010925379 A CN 202010925379A CN 112190555 B CN112190555 B CN 112190555B
- Authority
- CN
- China
- Prior art keywords
- ramelteon
- mannitol
- sublingual tablet
- percent
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000006190 sub-lingual tablet Substances 0.000 title claims abstract description 45
- 229940098466 sublingual tablet Drugs 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims description 27
- YLXDSYKOBKBWJQ-LBPRGKRZSA-N N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e]benzofuran-8-yl]ethyl]propanamide Chemical compound C1=C2OCCC2=C2[C@H](CCNC(=O)CC)CCC2=C1 YLXDSYKOBKBWJQ-LBPRGKRZSA-N 0.000 claims abstract description 83
- 229960001150 ramelteon Drugs 0.000 claims abstract description 83
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 21
- 239000000945 filler Substances 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 10
- 239000000796 flavoring agent Substances 0.000 claims abstract description 7
- 235000013355 food flavoring agent Nutrition 0.000 claims abstract description 7
- 239000000314 lubricant Substances 0.000 claims abstract description 7
- 239000000594 mannitol Substances 0.000 claims description 46
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 44
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 44
- 235000010355 mannitol Nutrition 0.000 claims description 41
- 229930195725 Mannitol Natural products 0.000 claims description 38
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 34
- 229960000913 crospovidone Drugs 0.000 claims description 29
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 29
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 29
- 229920002472 Starch Polymers 0.000 claims description 22
- 235000019359 magnesium stearate Nutrition 0.000 claims description 22
- 239000008107 starch Substances 0.000 claims description 22
- 235000019698 starch Nutrition 0.000 claims description 22
- 239000011734 sodium Substances 0.000 claims description 20
- 229910052708 sodium Inorganic materials 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 19
- 239000003826 tablet Substances 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 15
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 14
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 14
- 235000001050 hortel pimenta Nutrition 0.000 claims description 14
- 238000012216 screening Methods 0.000 claims description 13
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 9
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 9
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 9
- 244000246386 Mentha pulegium Species 0.000 claims description 8
- 238000000227 grinding Methods 0.000 claims description 7
- 238000005303 weighing Methods 0.000 claims description 4
- 238000010579 first pass effect Methods 0.000 abstract description 7
- 210000004185 liver Anatomy 0.000 abstract description 5
- 229940059362 ramelteon oral tablet Drugs 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 22
- 239000003814 drug Substances 0.000 description 10
- 239000007884 disintegrant Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 239000007935 oral tablet Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241001479543 Mentha x piperita Species 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 229940096978 oral tablet Drugs 0.000 description 6
- 210000002200 mouth mucosa Anatomy 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 229940069328 povidone Drugs 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 206010022437 insomnia Diseases 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000005550 wet granulation Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 102000001419 Melatonin receptor Human genes 0.000 description 2
- 108050009605 Melatonin receptor Proteins 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229940121723 Melatonin receptor agonist Drugs 0.000 description 1
- 102100024930 Melatonin receptor type 1A Human genes 0.000 description 1
- 101710098568 Melatonin receptor type 1A Proteins 0.000 description 1
- 102100024970 Melatonin receptor type 1B Human genes 0.000 description 1
- 101710098567 Melatonin receptor type 1B Proteins 0.000 description 1
- 102000004108 Neurotransmitter Receptors Human genes 0.000 description 1
- 108090000590 Neurotransmitter Receptors Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- -1 example 1) Chemical compound 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229910021487 silica fume Inorganic materials 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
雷美替胺 | 2.5g(0.25%) |
甘露醇 | 956g(95.6%) |
交联聚维酮 | 40g(4%) |
硬脂酸镁 | 1g(0.1%) |
薄荷香精 | 0.5g(0.05%) |
总计 | 1000g(100%) |
雷美替胺 | 2.5g(0.25%) |
甘露醇 | 956g(95.6%) |
交联聚维酮 | 20g(2%) |
羧甲基淀粉钠 | 20g(2%) |
硬脂酸镁 | 1g(0.1%) |
薄荷香精 | 0.5g(0.05%) |
总计 | 1000g(100%) |
雷美替胺 | 2.5g(0.25%) |
甘露醇 | 956g(95.6%) |
交联聚维酮 | 13.3g(1.33%) |
羧甲基淀粉钠 | 26.7g(2.67%) |
硬脂酸镁 | 1g(0.1%) |
薄荷香精 | 0.5g(0.05%) |
总计 | 1000g(100%) |
雷美替胺 | 2.5g(0.25%) |
甘露醇 | 956g(95.6%) |
交联聚维酮 | 10g(1%) |
羧甲基淀粉钠 | 30g(3%) |
硬脂酸镁 | 1g(0.1%) |
薄荷香精 | 0.5g(0.05%) |
总计 | 1000g(100%) |
雷美替胺 | 0.25g |
氯化钠 | 8g |
注射用水加至 | 1000mL |
雷美替胺 | 2.5g |
乳糖 | 1000g |
淀粉 | 150g |
羟丙纤维素 | 50g |
硬脂酸镁 | 1.5g |
总计 | 1204g |
薄膜包衣预混剂 | 30g |
雷美替胺 | 2.5g(0.25%) |
甘露醇 | 956g(95.6%) |
羧甲基淀粉钠 | 40g(4%) |
硬脂酸镁 | 1g(0.1%) |
薄荷香精 | 0.5g(0.05%) |
总计 | 1000g(100%) |
雷美替胺 | 2.5g(0.25%) |
甘露醇 | 956g(95.6%) |
羧甲纤维素 | 40g(4%) |
硬脂酸镁 | 1g(0.1%) |
薄荷香精 | 0.5g(0.05%) |
总计 | 1000g(100%) |
处方 | 含量 | 含量均匀度(A+2.2S) |
实施例1 | 0.251 | 3.21 |
对比例1 | 0.248 | 10.23 |
Claims (3)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910845772.8A CN110433142A (zh) | 2019-09-06 | 2019-09-06 | 一种雷美替胺舌下片及其制备方法 |
CN2019108457728 | 2019-09-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112190555A CN112190555A (zh) | 2021-01-08 |
CN112190555B true CN112190555B (zh) | 2023-05-12 |
Family
ID=68439652
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910845772.8A Pending CN110433142A (zh) | 2019-09-06 | 2019-09-06 | 一种雷美替胺舌下片及其制备方法 |
CN202010925379.2A Active CN112190555B (zh) | 2019-09-06 | 2020-09-06 | 一种雷美替胺舌下片及其制备方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910845772.8A Pending CN110433142A (zh) | 2019-09-06 | 2019-09-06 | 一种雷美替胺舌下片及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN110433142A (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110433142A (zh) * | 2019-09-06 | 2019-11-12 | 杭州百诚医药科技股份有限公司 | 一种雷美替胺舌下片及其制备方法 |
CN113274364B (zh) * | 2021-07-22 | 2021-12-07 | 海南慧谷药业有限公司 | 雷美替胺缓释制剂及其制备方法 |
CN115645490B (zh) * | 2022-12-12 | 2023-05-16 | 元和药业股份有限公司 | 一种用于咽炎的片剂及其制备方法 |
CN115778925A (zh) * | 2022-12-26 | 2023-03-14 | 湖北广济医药科技有限公司 | 一种雷美替胺口溶膜剂及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013054582A1 (en) * | 2011-10-14 | 2013-04-18 | Takeda Pharmaceutical Company Limited | Orally dispersible tablet |
CN106880610A (zh) * | 2015-12-15 | 2017-06-23 | 北大方正集团有限公司 | 一种雷美替胺分散片及其制备方法 |
CN108310298A (zh) * | 2018-05-09 | 2018-07-24 | 深圳康歌眼保健防控科技研究院 | 一种具有缓解眼疲劳、防治近视的中药组合物及制备方法 |
CN110433142A (zh) * | 2019-09-06 | 2019-11-12 | 杭州百诚医药科技股份有限公司 | 一种雷美替胺舌下片及其制备方法 |
CN111067874A (zh) * | 2020-01-10 | 2020-04-28 | 威海百合生物技术股份有限公司 | 一种b族维生素直压片剂及其制备方法 |
-
2019
- 2019-09-06 CN CN201910845772.8A patent/CN110433142A/zh active Pending
-
2020
- 2020-09-06 CN CN202010925379.2A patent/CN112190555B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013054582A1 (en) * | 2011-10-14 | 2013-04-18 | Takeda Pharmaceutical Company Limited | Orally dispersible tablet |
CN106880610A (zh) * | 2015-12-15 | 2017-06-23 | 北大方正集团有限公司 | 一种雷美替胺分散片及其制备方法 |
CN108310298A (zh) * | 2018-05-09 | 2018-07-24 | 深圳康歌眼保健防控科技研究院 | 一种具有缓解眼疲劳、防治近视的中药组合物及制备方法 |
CN110433142A (zh) * | 2019-09-06 | 2019-11-12 | 杭州百诚医药科技股份有限公司 | 一种雷美替胺舌下片及其制备方法 |
CN111067874A (zh) * | 2020-01-10 | 2020-04-28 | 威海百合生物技术股份有限公司 | 一种b族维生素直压片剂及其制备方法 |
Non-Patent Citations (3)
Title |
---|
国产红霉素肠溶片的质量分析;武建卓等;《中国抗生素杂志》;20190331;第44卷;第308-312页 * |
鄢海燕等.薄荷.《药剂学》.江苏凤凰科学技术出版社,2018,第149页. * |
金向群等.含量.《药学专业知识(二)》.金盾出版社,2012, * |
Also Published As
Publication number | Publication date |
---|---|
CN112190555A (zh) | 2021-01-08 |
CN110433142A (zh) | 2019-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112190555B (zh) | 一种雷美替胺舌下片及其制备方法 | |
TW201815384A (zh) | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 | |
CN101229148A (zh) | 硝酸甘油口腔(舌下)崩解片的制剂及其制备方法 | |
CN107137399A (zh) | 一种用于麻醉的舌下片及其制备方法 | |
CN109662949A (zh) | 一种醋酸氟氢可的松口腔崩解片及其制备方法 | |
CN107362150B (zh) | 一种盐酸可乐定冻干口崩片及其制备方法 | |
CN106943367B (zh) | 一种马来酸阿法替尼片及其制备方法 | |
Kushwaha et al. | An Overview on Formulation and Evaluation Aspects of Tablets | |
CN113274364B (zh) | 雷美替胺缓释制剂及其制备方法 | |
CN117442577B (zh) | 一种坎地沙坦酯微片及制备方法和应用 | |
CN112315927A (zh) | 一种帕利哌酮缓释口崩片及其制备方法 | |
CN115154431B (zh) | 一种硝酸甘油片剂及其制备方法 | |
CN114404374B (zh) | 一种硝酸甘油微片及其制备方法和制剂 | |
CN114129528B (zh) | 一种具有临床优势的新型枸橼酸西地那非制剂及其制备工艺与应用 | |
CN113827576B (zh) | 一种活性成分为草酸纳洛解的药物组合物及制备方法 | |
CN106309395A (zh) | 一种他克莫司缓释片及其制备方法 | |
JPWO2017047586A1 (ja) | 錠剤 | |
CN106880611A (zh) | 一种含微粉化的托伐普坦和水溶性辅料的托伐普坦制剂 | |
CN112386578B (zh) | 一种孟鲁司特钠咀嚼片及其制备方法 | |
CN109846843B (zh) | 地氯雷他定口腔崩解片 | |
CN101375852B (zh) | 富马酸喹硫平口服制剂及其制备方法 | |
Chaturvedi et al. | Comparative Evaluation Of Natural And Semisynthetic Superdisintegrants In The Formulation Of Orodispersible Tablets of Norfloxacin | |
Naji et al. | Design and in vitro evaluation of acrivastine as orodispersible tablet using direct compression method | |
Chaturvedi et al. | Impact of superdisintegrants on the release of oro-dispersible tablets of losartan potassium: A comparative analysis | |
CN114224855B (zh) | 一种甲磺酸多沙唑嗪口含片及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 311100 No. 802, 8th floor, building 1, No. 502, Linping Avenue, Yuhang Economic and Technological Development Zone, Linping District, Hangzhou City, Zhejiang Province Applicant after: HANGZHOU BIO-SINCERITY PHARMA-TECH Co.,Ltd. Address before: 311103 B203, building 1, 9 Zhenxing East Road, Yuhang Economic and Technological Development Zone, Yuhang District, Hangzhou City, Zhejiang Province Applicant before: HANGZHOU BIO-SINCERITY PHARMA-TECH Co.,Ltd. |
|
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Zou Yonghua Inventor after: Chen Xiaoping Inventor after: Shen Yikang Inventor after: Lou Jinfang Inventor after: Li Qingqing Inventor after: Xiong Weiyan Inventor after: Shen Ximing Inventor before: Chen Xiaoping Inventor before: Shen Yikang Inventor before: Zou Yonghua Inventor before: Lou Jinfang Inventor before: Li Qingqing Inventor before: Xiong Weiyan Inventor before: Shen Ximing |
|
GR01 | Patent grant | ||
GR01 | Patent grant |